ArticlemedRxiv : the preprint server for health sciences2025
Association of [
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated byAssociation of [2026
Authors and funding
18 authors.
Funding
Abstract
Background and objectives: Evaluating tau biomarkers in patients with available autopsy data is critical for validating their sensitivity and specificity to detect Alzheimer's disease neuropathologic changes (ADNC). We examined the association between tau-PET (using [ Methods: We analyzed Flortaucipir-PET (80-100 minutes post-injection acquisition, normalized to inferior cerebellar cortex) from 73 patients with a clinical diagnosis of various neurodegenerative diseases who underwent autopsy at the Neurodegenerative Disease Brain Bank (median [IQR] age: 67 [59, 73] years, 60% male, median [IQR] PET-to-autopsy duration: 3.9 years, [2.1, 5.1]). Standardized uptake value ratios (SUVRs) were extracted from the entorhinal cortex (an early tau region) and the temporal meta-ROI (a widely used AD signature region). A semi-quantitative rating of AD NFT burden in cortical areas was available for 56 participants. Plasma p-tau217 was quantified with Simoa (Janssen Results: Our cohort included patients with a primary pathological diagnosis of AD (n=39), FTLD (tauopathies n=28, non-tauopathies n=4), and Lewy body dementia (n=2). Flortaucipir SUVRs were elevated in patients with a neuropathological diagnosis of AD compared with non-AD patients. Consistently elevated PET signal was detected in both the entorhinal cortex and temporal meta-ROI of patients with neurofibrillary tangle (NFT) at Braak stage VI and with high ADNC levels. No elevation of Flortaucipir SUVRs was observed at intermediate levels of ADNC. The burden of AD NFTs was correlated with local Flortaucipir SUVRs across cortical brain regions. Plasma p-tau217 concentrations were increased in patients at Braak stage V and VI and strongly correlated with Flortaucipir SUVRs across ROIs (r's≥0.75), driven by Braak V-VI cases. Flortaucipir SUVRs and plasma p-tau217 concentrations identified high Braak stages (V-VI) and high/intermediate ADNC levels with similarly high performance (area under the curve≥ 0.90). Discussion: Flortaucipir-PET and plasma p-tau217 both displayed strong specificity for primary AD neuropathological diagnosis but lacked sensitivity to detect early AD-related tau co-pathology in patients with a non-AD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.